Other
Nijmegen Breakage Syndrome
1
Pipeline Programs↗
2
Active Trials↗
1
Companies Involved↗
Nijmegen breakage syndrome is an early-stage landscape with 1 program across 1 company. The most active players are Medexus Pharma, Inc..
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical
No programs
Phase 1
No programs
Phase 21
Phase 3
No programs
Approved
No programs
Analysis
Trial Status
3
clinical trials
Recruiting1 · 33%
Unknown status1 · 33%
Not yet recruiting1 · 33%
Clinical Trials
Trial Activity
Low Dose Treosulfan Based Conditioning Regimen and PTCy in HSCT for Nijmegen Breakage Syndrome
Recruiting·FFederal Research Institute of Pediatric Hematology, Oncology and Immunology·Phase 2·NCT06198842·10 enrolled
Low Dose Treosulfan Based Conditioning Regimen in HSCT for Nijmegen Breakage Syndrome
Unknown status·FFederal Research Institute of Pediatric Hematology, Oncology and Immunology·Phase 2·NCT04400045·10 enrolled
Study of Treosulfan-Based Conditioning for HSCT in Nijmegen Breakage Syndrome
Not yet recruiting·FFederal Research Institute of Pediatric Hematology, Oncology and Immunology·Phase 2·NCT07316595·24 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)